Titre : Mitogen-Activated Protein Kinase 3

Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes", "headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Extracellular Signal-Regulated MAP Kinases", "url": "https://questionsmedicales.fr/mesh/D048049", "about": { "@type": "MedicalCondition", "name": "Extracellular Signal-Regulated MAP Kinases", "code": { "@type": "MedicalCode", "code": "D048049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.567.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3", "alternateName": "Mitogen-Activated Protein Kinase 3", "code": { "@type": "MedicalCode", "code": "D048052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Juan Wang", "url": "https://questionsmedicales.fr/author/Juan%20Wang", "affiliation": { "@type": "Organization", "name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea." } }, { "@type": "Person", "name": "Mohammad Shafiq", "url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Kumaravelu Jagavelu", "url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Neeraj Kumar Verma", "url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Jimut Kanti Ghosh", "url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.", "datePublished": "2023-09-09", "url": "https://questionsmedicales.fr/article/37862797", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejca.2023.113337" } }, { "@type": "ScholarlyArticle", "name": "Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy.", "datePublished": "2023-02-20", "url": "https://questionsmedicales.fr/article/36825932", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/DAD.0000000000002392" } }, { "@type": "ScholarlyArticle", "name": "Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor.", "datePublished": "2023-08-01", "url": "https://questionsmedicales.fr/article/37642071", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.31557/APJCP.2023.24.8.2829" } }, { "@type": "ScholarlyArticle", "name": "Analysis of Programmed Cell Death-1 (PD-1) Gene Variations (re11568821 and rs41386349) in HTLV-1 Infection Using One Primer Pair and Proviral Load.", "datePublished": "2023-04-05", "url": "https://questionsmedicales.fr/article/37020064", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00239-023-10104-5" } }, { "@type": "ScholarlyArticle", "name": "Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.", "datePublished": "2022-07-16", "url": "https://questionsmedicales.fr/article/35868194", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ctrv.2022.102437" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Mitogen-Activated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D020928" }, { "@type": "ListItem", "position": 7, "name": "Extracellular Signal-Regulated MAP Kinases", "item": "https://questionsmedicales.fr/mesh/D048049" }, { "@type": "ListItem", "position": 8, "name": "Mitogen-Activated Protein Kinase 3", "item": "https://questionsmedicales.fr/mesh/D048052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3", "description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitogen-Activated Protein Kinase 3", "description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitogen-Activated Protein Kinase 3", "description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitogen-Activated Protein Kinase 3", "description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitogen-Activated Protein Kinase 3", "description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3", "description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de MAPK3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer MAPK3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de phosphorylation et les analyses protéomiques sont courants." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à MAPK3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3." } }, { "@type": "Question", "name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des cancers et des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner une inflammation et des douleurs." } }, { "@type": "Question", "name": "MAPK3 affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à MAPK3 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3." } }, { "@type": "Question", "name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements de MAPK3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter pour MAPK3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé." } }, { "@type": "Question", "name": "Le stress peut-il affecter MAPK3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation de MAPK3." } }, { "@type": "Question", "name": "Des exercices spécifiques aident-ils MAPK3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3." } }, { "@type": "Question", "name": "La gestion du poids influence-t-elle MAPK3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quels traitements ciblent MAPK3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger MAPK3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3." } }, { "@type": "Question", "name": "Quels médicaments affectent la voie MAPK3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour MAPK3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle MAPK3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "MAPK3 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment MAPK3 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "MAPK3 peut-elle influencer le vieillissement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à MAPK3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus." } }, { "@type": "Question", "name": "L'âge influence-t-il l'activité de MAPK3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il MAPK3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Des infections peuvent-elles affecter MAPK3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber la signalisation de MAPK3." } } ] } ] }

Sources (10000 au total)

Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.

Epstein-Barr virus-associated intrahepatic cholangiocarcinoma (EBVaICC) has a distinct genomic profile and increased CD3... Patients with metastatic biliary tract cancer (BTC) diagnosed at Sun Yat-sen University Cancer Center from January 2016 to December 2021 were identified. In situ hybridisation was performed to detect ... A total of 698 patients with metastatic BTC were identified, of whom 39 (5.6%) had EBVaICC. Among the 136 patients who were not administered PD-1 antibody, the OS was similar between patients with EBV... This study identified a clinically actionable subset of patients with EBVaICC with a promising response to the PD-1 antibody....

Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy.

Lichen planus pemphigoides (LPPemph), apart from bullous pemphigoid, is a rare bullous dermatosis that can be induced by programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors. The prim...

Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor.

Programmed death ligand 1 (PD-L1) plays critical role in PD-1-dependent immunity suppress. Abnormal PD-L1 expression has shown to be directly related to poor prognosis and drug resistance in cancer pa... In this cross-sectional study, 100 patients with HL between 2007 and 2015, were included. A thin section of tumor tissue fixed and processed on slides, stained by immunohistochemistry (IHC) PD-L1 spec... of 100 HL cases, the mean age of 33 relapsed group cases was significantly higher than remission group (p-value = 0.006), and gender was not significant however majority of cases in both groups were m... PD-L1 expression assessment in HL patients is a valuable tool for prediction of the disease subtype, progression, stage, and treatment outcome. IHC method as an available, simple, rather cheap, and ef...

Analysis of Programmed Cell Death-1 (PD-1) Gene Variations (re11568821 and rs41386349) in HTLV-1 Infection Using One Primer Pair and Proviral Load.

About 90% of people infected with Human T lymphotropic virus type-1 (HTLV-1) virus are asymptomatic, so it can be said that the prevalence of this virus is not completely clear. During chronic infecti...

Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.

Immunotherapy and in particular programmed cell death protein 1 (PD-1) inhibitors have been applied not only in the management of recurrent or metastatic disease but also as component of potentially c...

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.

Programmed cell death-1 (PD-1) inhibitor was proven to be useful for the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients. Though both PD-1 inhibitor alone and combination wi... We consecutively enrolled the R/M HNSCC patients treated with concurrent PD-1 inhibitor and chemoradiotherapy from August 2018 to April 2022 in Sichuan Cancer hospital. All the patients received the c... 40 R/M HNSCC patients were enrolled in our stuty. The median follow up time was 14 months. 22 patients had recurrent disease only, 16 patients had metastatic disease only, and 2 patients had both recu... The synergy of concurrent PD-1 inhibitor treatment with chemoradiotherapy shows promise as a treatment strategy and an acceptable toxicity for the R/M HNSCC patients....

Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.

Immune checkpoint inhibitors (ICIs) have made an important contribution to the survival of patients with certain cancers. ICIs interrupt co-inhibitory signaling pathways mediated by programmed cell de...

Association of programmed cell death 1 (PD-1) gene polymorphism (rs10204525) with COVID-19 severity and mortality: A case-control study in the Iranian population.

Programmed cell death 1 (PD-1), as a negative immune regulator, regulates the activation of T cells and maintains the immune system's homeostasis. Previous studies suggest that the effective immune re... The PD-1 rs10204525 was genotyped in 810 COVID-19 patients and 164 healthy individuals as a control group using Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Moreover,... Regarding disease severity and mortality, no significant differences were detected between study groups in alleles and genotypes frequency distribution under different inheritance models. We found tha... Considering the lack of significant differences in PDCD-1 expression in different genotypes in the control group, lower expression of PDCD-1 in COVID-19 patients carrying the G allele suggests the imp...